Granted Patent
B2
US 12,558,362 · App. 18/006,127 · Granted Feb 24, 2026
Use of cannabidiol in the treatment of seizures associated with rett syndrome
Assignee:
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with Rett syndrome. In a further embodiment the types of seizures include tonic, tonic-clonic, absence seizures and focal seizures with impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.
Claims (13)
1 . A method for treating seizures associated with Rett syndrome comprising administering a cannabidiol (CBD) preparation, wherein the seizures associated with Rett syndrome are tonic, tonic-clonic, absence, and focal seizures with impairment.
2 . The method of claim 1 , wherein the CBD preparation comprises greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC).
3 . The method of claim 1 , wherein the CBD preparation comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids, wherein the less than or equal to 2% (w/w) other cannabinoids comprise the cannabinoids tetrahydrocannabinol (THC); cannabidiol-C1 (CBD-C1); cannabidivarin (CBDV); and cannabidiol-C4 (CBD-C4), and wherein the THC is present as a mixture of trans-THC and cis-THC.
4 . The method of claim 1 , wherein the CBD preparation is used in combination with one or more concomitant anti-epileptic drugs (AED).
5 . The method of claim 4 , wherein the one or more AED is selected from the group consisting of: clobazam, levetiracetam, zonisamide, valproic acid, perampanel, clonazepam and diazepam.
6 . The method of claim 1 , wherein the CBD that is present is isolated from cannabis plant material.
7 . The method of claim 1 , wherein at least a portion of at least one of the cannabinoids present in the CBD preparation is isolated from cannabis plant material.
8 . The method of claim 1 , wherein the CBD is present as a synthetic preparation.
9 . The method of claim 8 , wherein at least a portion of at least one of the cannabinoids present in the CBD preparation is prepared synthetically.
10 . The method of claim 1 , wherein the dose of CBD is greater than 5 mg/kg/day.
11 . The method of claim 1 , wherein the dose of CBD is 20 mg/kg/day.
12 . The method of claim 1 , wherein the dose of CBD is 25 mg/kg/day.
13 . The method of claim 1 , wherein the dose of CBD is 50 mg/kg/day.
Assignments (3)
CHANGE OF NAME
Recorded May 19, 2025
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 071152/0832 →
SECURITY AGREEMENT
Recorded Jul 26, 2024
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; GW PHARMA LIMITED; JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (F/K/A GW RESEARCH LIMITED)
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 068173/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 29, 2023
From: CHECKETTS, DANIEL ADAM; CRAIG, KEVIN JAMES
To: GW RESEARCH LIMITED
Reel/Frame 064428/0186 →
Priority Claims (1)
GB 2011174
· Jul 20, 2020
· national
Continuity (1)
References Cited (189)
US 8632825B2
· Velasco Diez et al.
· 2014
[cited by applicant]
US 8790719B2
· Parolaro et al.
· 2014
[cited by applicant]
US 9017737B2
· Kikuchi et al.
· 2015
[cited by applicant]
US 9125859B2
· Whalley et al.
· 2015
[cited by applicant]
US 9474726B2
· Guy et al.
· 2016
[cited by applicant]
US 9949936B2
· Guy et al.
· 2018
[cited by applicant]
US 9949937B2
· Guy et al.
· 2018
[cited by applicant]
US 9956183B2
· Guy et al.
· 2018
[cited by applicant]
US 9956184B2
· Guy et al.
· 2018
[cited by applicant]
US 9956185B2
· Guy et al.
· 2018
[cited by applicant]
US 9956186B2
· Guy et al.
· 2018
[cited by applicant]
US 20150359756A1
· Guy et al.
· 2015
[cited by applicant]
US 20170239193A1
· Guy et al.
· 2017
[cited by applicant]
US 20170349517A1
· Dickman et al.
· 2017
[cited by applicant]
US 20180071210A1
· Wilkhu et al.
· 2018
[cited by applicant]
US 20180228751A1
· Stott et al.
· 2018
[cited by applicant]
US 20190167583A1
· Shah
· 2019
[cited by applicant]
US 20190314296A1
· Wright et al.
· 2019
[cited by applicant]
US 20190321307A1
· Guy et al.
· 2019
[cited by applicant]
US 20190365667A1
· Wright et al.
· 2019
[cited by applicant]
US 20200138738A1
· Guy et al.
· 2020
[cited by applicant]
US 20200179303A1
· Guy et al.
· 2020
[cited by applicant]
US 20200206153A1
· Whalley et al.
· 2020
[cited by applicant]
US 20200237683A1
· Whalley et al.
· 2020
[cited by applicant]
US 20200297656A1
· Guy et al.
· 2020
[cited by applicant]
US 20200352878A1
· Guy et al.
· 2020
[cited by applicant]
US 20210015789A1
· Guy et al.
· 2021
[cited by applicant]
US 20210052512A1
· Guy et al.
· 2021
[cited by applicant]
US 20210059949A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210059960A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210059976A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210169824A1
· Guy et al.
· 2021
[cited by applicant]
US 20210177773A1
· Guy et al.
· 2021
[cited by applicant]
US 20210290565A1
· Guy et al.
· 2021
[cited by applicant]
US 20210330636A1
· Guy et al.
· 2021
[cited by applicant]
US 20210401771A1
· Guy et al.
· 2021
[cited by applicant]
US 20220000800A1
· Guy et al.
· 2022
[cited by applicant]
US 20220008355A1
· Guy et al.
· 2022
[cited by applicant]
US 20220016048A1
· Guy et al.
· 2022
[cited by applicant]
US 20220023232A1
· Guy et al.
· 2022
[cited by applicant]
US 20220040155A1
· Guy et al.
· 2022
[cited by applicant]
US 20220062197A1
· Stott et al.
· 2022
[cited by applicant]
US 20220062211A1
· Stott et al.
· 2022
[cited by applicant]
US 20220087951A1
· Knappertz
· 2022
[cited by applicant]
US 20220096397A1
· Wright et al.
· 2022
[cited by applicant]
US 20220168266A1
· Guy et al.
· 2022
[cited by applicant]
US 20220183997A1
· Guy et al.
· 2022
[cited by applicant]
US 20220184000A1
· Guy et al.
· 2022
[cited by applicant]
US 20220202738A1
· Guy et al.
· 2022
[cited by applicant]
US 20220211629A1
· Wilkhu et al.
· 2022
[cited by applicant]
US 20220226257A1
· Guy et al.
· 2022
[cited by applicant]
US 20220233495A1
· Silcock et al.
· 2022
[cited by applicant]
US 20220249396A1
· Guy et al.
· 2022
[cited by applicant]
US 20220257529A1
· Guy et al.
· 2022
[cited by applicant]
US 20220265573A1
· Guy et al.
· 2022
[cited by applicant]
US 20220288055A1
· Silcock et al.
· 2022
[cited by applicant]
US 20220378714A1
· Guy et al.
· 2022
[cited by applicant]
US 20220387350A1
· Guy et al.
· 2022
[cited by applicant]
US 20220395471A1
· Guy et al.
· 2022
[cited by applicant]
US 20230000789A1
· Guy et al.
· 2023
[cited by applicant]
US 20230022487A1
· Guy et al.
· 2023
[cited by applicant]
US 20230024312A1
· Whalley et al.
· 2023
[cited by applicant]
US 20230026079A1
· Guy et al.
· 2023
[cited by applicant]
US 20230032502A1
· Guy et al.
· 2023
[cited by applicant]
US 20230038423A1
· Silcock et al.
· 2023
[cited by applicant]
US 20230068885A1
· Guy et al.
· 2023
[cited by applicant]
US 20230143812A1
· Knappertz et al.
· 2023
[cited by applicant]
US 20230235825A1
· Thompson et al.
· 2023
[cited by applicant]
US 20230248664A1
· Guy
· 2023
[cited by applicant]
US 20230277560A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277561A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277562A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277563A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285419A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285420A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285421A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285422A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285423A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285424A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285426A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285428A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230301934A1
· Whalley et al.
· 2023
[cited by applicant]
US 20230301936A1
· Guy et al.
· 2023
[cited by applicant]
US 20230310464A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230346809A1
· Craig
· 2023
[cited by applicant]
US 20230372367A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230372368A1
· Checketts et al.
· 2023
[cited by applicant]
US 20240016819A1
· Craig
· 2024
[cited by applicant]
US 20240025858A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240033229A1
· Guy et al.
· 2024
[cited by applicant]
US 20240033272A1
· Checketts et al.
· 2024
[cited by applicant]
US 20240050452A1
· Craig et al.
· 2024
[cited by applicant]
US 20240091241A1
· Guy et al.
· 2024
[cited by applicant]
US 20240130981A1
· Wilkhu
· 2024
[cited by applicant]
US 20240131041A1
· Tse
· 2024
[cited by applicant]
US 20240165048A1
· Guy
· 2024
[cited by applicant]
US 20240207220A1
· Guy et al.
· 2024
[cited by applicant]
US 20240215910A1
· Tse et al.
· 2024
[cited by applicant]
US 20240226032A9
· Wilkhu et al.
· 2024
[cited by applicant]
US 20240226123A9
· Tse
· 2024
[cited by applicant]
US 20240238218A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240254066A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240254072A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240261234A1
· Guy
· 2024
[cited by applicant]
EP 2311475A2
· 2011
[cited by applicant]
GB 2487183A
· 2012
[cited by applicant]
GB 2539472A
· 2016
[cited by applicant]
GB 2542797A
· 2017
[cited by applicant]
GB 2569961A
· 2019
[cited by applicant]
WO WO2011121351A1
· 2011
[cited by applicant]
WO WO2015193667A1
· 2015
[cited by applicant]
WO WO2015193668A1
· 2015
[cited by applicant]
WO WO2016094810A2
· 2016
[cited by applicant]
WO WO2016203239A1
· 2016
[cited by applicant]
WO WO2017178807A1
· 2017
[cited by applicant]
WO WO2018061007A1
· 2018
[cited by applicant]
WO WO2018205022A1
· 2018
[cited by applicant]
WO WO2019135075A1
· 2019
[cited by applicant]
WO WO2019207319A1
· 2019
[cited by applicant]
WO WO2020105005A1
· 2020
[cited by applicant]
WO WO2020112460A1
· 2020
[cited by applicant]
WO WO2021079148A1
· 2021
[cited by applicant]
Amada, N. et al., “Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression,” 2013, PeerJ, 1:e214; 18 pages; http://dx.doi.org/10.7717/peerj.214.
[cited by applicant]
Clinical Trials.Gov [online], Identifier: NCT03848832, Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome (ARCH), Jazz Pharmaceuticals, U.S. National Library of Medicine…
[cited by applicant]
Eadie, Shortcomings in the current treatment of epilepsy, Expert Rev Neurother, 12(12):1419-1427 (2012).
[cited by applicant]
Elsohly, M. & Gul, W., Handbook of Cannabis, Chapter 1, Constituents of Cannabis Sativa, Roger Pertwee, Ed., 2012, 21 pages.
[cited by applicant]
European Medicines Agency, Public summary of opinion on orphan designation, Cannabidivarin for the treatment of Rett syndrome, Jan. 5, 2018, 4 pages; www.ema.europa.eu/contact.
[cited by applicant]
Gaoni, Y. & Mechoulam, R., “Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish,” J. Am. Chern. Soc. 1964, 86, 8, 1646-1647.
[cited by applicant]
Gaoni, Y. & Mechoulam, R., “The Isolation and Structure of Δ1-Tetrahydrocannabinol and Other Neutral Cannabinoids from Hashish,” J Am Chern Soc. Jan. 13, 1971;93(1):217-24. doi: 10.1021/ja00730a036.
[cited by applicant]
Guidance for Industry, Botanical Drug Development, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); Dec. 2016, Pharmaceutical Quality/CMC, 34 pa…
[cited by applicant]
Hill, “Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB 1 receptor-independent mechanism,” British Journal of Pharmacology, 170(3): 679-692 (2013).
[cited by applicant]
Hill et al., “Cannabidivarin is anticonvulsant in mouse and rat,” Br J Pharmacol, 167(8):1629-1642 (2012).
[cited by applicant]
Huizenga, M. N. et al., Preclinical safety and efficacy of cannabidivarin for early life seizures, Neuropharmacology. Apr. 2019 ; 148: 189-198. doi:10.1016/j.neuropharm.2019.01.002.
[cited by applicant]
Kwan et al., Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies, Epilepsia. Jun. 2010;51(6):1069-77.doi:10.1111/j.1528-1167.2009.02397.x. …
[cited by applicant]
Lewis, M. M. et al., Chemical Profiling of Medical Cannabis Extracts, ACS Omega, 2:6091-9103, 2017; doi:10.1021/acsomega.7b00996.
[cited by applicant]
Mouro, F. M. et al., From Cannabinoids and Neurosteroids to Statins and the Ketogenic Diet: New Therapeutic Avenues in Rett Syndrome?, Frontiers in Neuroscience, vol. 13, Article 680, Jul. 2019, 22 pages; https://www.fr…
[cited by applicant]
Sands, T. et al., Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US, CNS Drugs, 33:47-60 (2019).
[cited by applicant]
Schafroth, M. A. et al., “Sterodivergent Total Synthesis of Δ9-Tetrahydrocannabinols,” Angew. Chem. Int. Ed., 53:13898-13901 (2014).
[cited by applicant]
Smith, R. M. & Kempfert, K. D., “Δ1-3,4-C/S-Tetrahydrocannabinol in Cannabis Sativa,” Phytochemistry, 16:1088-1089 (1977).
[cited by applicant]
Sulak, D. et al., The current status of artisanal cannabis for the treatment of epilepsy in the United States, Epilepsy & Behavior, 70:328-333 (2017).
[cited by applicant]
Thurman et al., “Standards for epidemiologic studies and surveillance of epilepsy,” Epilepsia, 52 (Suppl 7):2-26 (2011).
[cited by applicant]
Trost, B. M. & Dogra, K., “Synthesis of (-)-Δ9-trans-Tetrahydrocannabinol: Stereocontrol via Mo-Catalyzed Asymmetric Allylic Alkylation Reaction,” Organic Letters, 9(5):861-863 (2007).
[cited by applicant]
Vigli, D. et al., Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome, Neuropharmacology, 140:121-129 (2018).
[cited by applicant]
Way, K., How One Canna-Mom Treats Her Daughter's Rett Syndrome With Cannabis, 2023, https://cannabisnow.com/how-one-canna-mom-treats-her-daughters-rett-syndrome-with-cannabis/, 15 pages.
[cited by applicant]
Zamberletti, E. et al., Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice, Journal of Psychopharmacology, 2019, vol. 33(7) 894-907; https://doi.org/…
[cited by applicant]
Harvey, D. J., “Characterization of the Butyl Homologues of Delta1-tetrahydrocannabinol, Cannabinol and Cannabidiol in Samples of Cannabis by Combined Gas Chromatography and Mass Spectrometry,” J. Pharm. Pharmac., 28:28…
[cited by applicant]
Morales, P. et al., “An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol,” Frontiers in Pharmacology, 8:422 (2017); doi:10.3389/fphar.2017.00422, 18 pages.
[cited by applicant]
clinical trials.gov [online], Identifier: NCT03202303, Cannabidivarin (CBVD) vs. Placebo in Children With Autism Spectrum Disorder (ASD), Montefiore Medical Center, National Center for Biotechnology, last update posted …
[cited by applicant]
EPIDIOLEX (cannabidiol) oral solution, CV, Prescribing Information, 2018, [retrieval date unknown], 30 pages; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf.
[cited by applicant]
Pertwee, R. G., “The Pharmacology and Therapeutic Potential of Cannabidiol,” Cannabinoids, Chapter 3, DiMarzo, V. (Ed.), pp. 32-83 (2004).
[cited by applicant]
Takahashi, S., “Understanding the pathogenesis of Rett syndrome—Clinical features associated with mutations in the causative genes (MECP2, CDKL5, FOXG1), ” Brain and Development, 46:117-20 (2014), with English translati…
[cited by applicant]